On October 9, Iovance Biotherapeutics, Inc. rose 5.62% in regular trading, trading at $14.058 per share, with turnover of $32.39 million.

The move follows the company's announcement on October 1 of the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, which took place after a sharp rally driven by raised 2026 revenue guidance and a subsequent pullback, with buying support now returning to the stock.

Iovance Biotherapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing cell therapies using autologous tumor infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy for adult patients with unresectable or metastatic melanoma, and Proleukin, an interleukin-2 product for metastatic renal cell carcinoma.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)